Gwen Zwingenberger
Munich, BY 81675, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Journal: BMC cancer
Published: August 14, 2021
Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer.
Journal: Clinical and translational medicine
Published: June 16, 2021
Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Journal: BMC cancer
Published: November 23, 2020
Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Journal: BMC cancer
Published: December 18, 2019
MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Journal: PloS one
Published: July 12, 2019
Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines.
Journal: PLoS computational biology
Published: May 27, 2019
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
Journal: Molecular oncology
Published: August 22, 2017
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.
Journal: Journal of cancer research and clinical oncology
Published: September 08, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026